TESARO’s (TSRO) “Outperform” Rating Reiterated at Wells Fargo & Co
Wells Fargo & Co restated their outperform rating on shares of TESARO (NASDAQ:TSRO) in a report issued on Wednesday, The Fly reports. Wells Fargo & Co currently has a $122.00 price target on the biopharmaceutical company’s stock, down from their previous price target of $224.00.
Several other research analysts also recently commented on TSRO. Royal Bank of Canada reduced their price target on shares of TESARO to $48.00 and set a sector perform rating on the stock in a research note on Wednesday. Evercore ISI raised shares of TESARO from an in-line rating to an outperform rating and set a $88.00 price target on the stock in a research note on Thursday, February 22nd. Leerink Swann reaffirmed an outperform rating and issued a $105.00 price target (down previously from $123.00) on shares of TESARO in a research note on Wednesday. Barclays reduced their price target on shares of TESARO from $135.00 to $90.00 and set an equal weight rating on the stock in a research note on Wednesday. Finally, Cann reaffirmed a buy rating and issued a $122.00 price target (down previously from $199.00) on shares of TESARO in a research note on Tuesday, February 27th. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of Buy and an average target price of $133.39.
TESARO (NASDAQ TSRO) opened at $57.68 on Wednesday. TESARO has a 12 month low of $52.20 and a 12 month high of $184.00. The company has a debt-to-equity ratio of 0.34, a current ratio of 4.73 and a quick ratio of 4.35.
In other news, SVP Martin H. Jr. Huber sold 829 shares of TESARO stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $85.24, for a total value of $70,663.96. Following the transaction, the senior vice president now owns 8,101 shares of the company’s stock, valued at approximately $690,529.24. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 40.50% of the stock is owned by insiders.
Several institutional investors have recently modified their holdings of TSRO. TimesSquare Capital Management LLC grew its position in shares of TESARO by 226.1% in the 4th quarter. TimesSquare Capital Management LLC now owns 856,600 shares of the biopharmaceutical company’s stock worth $70,986,000 after buying an additional 593,924 shares during the last quarter. Renaissance Technologies LLC grew its position in shares of TESARO by 482.1% in the 4th quarter. Renaissance Technologies LLC now owns 357,400 shares of the biopharmaceutical company’s stock worth $29,618,000 after buying an additional 296,000 shares during the last quarter. Pictet Asset Management Ltd. grew its position in shares of TESARO by 58.1% in the 3rd quarter. Pictet Asset Management Ltd. now owns 630,904 shares of the biopharmaceutical company’s stock worth $81,450,000 after buying an additional 231,799 shares during the last quarter. BlackRock Inc. grew its position in shares of TESARO by 5.6% in the 4th quarter. BlackRock Inc. now owns 4,067,066 shares of the biopharmaceutical company’s stock worth $337,039,000 after buying an additional 213,920 shares during the last quarter. Finally, Element Capital Management LLC purchased a new position in shares of TESARO in the 4th quarter worth approximately $16,302,000.
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.